Ja, Nexstim har planlagt at bruge pengene på et eller andet; kerneforretningen har næppe brug for en sådan ordning. I Bittiums rapporter finder man følgende om deres neuro-forretning:
“EEG and EMG solutions will remain in the company’s portfolio, but as the markets for these products are still developing, the company will continue to analyse the market potential, and develop the product portfolio accordingly.”
"The market for long-term EEG measurement is in its early stages of development. The operating environment and customer base differ from Cardiac and Sleep solutions, and the device is designed for use in intensive care. The greatest market potential for Bittium BrainStatus EEG devices is in the United States, but the product does not currently have FDA approval. Bittium continues to analyse the market and develop the product in the long-term to meet market requirements.
Bittium’s EMG device for measuring muscle activation is based on Bittium’s Faros technology and is intended for monitoring the progress of rehabilitation or identifying various muscle or movement disorders, such as Parkinson’s disease. Bittium continues to sell the device to its current customer but has decided not to make any broader commitments in this product area."
Bittiums medical-forretning leverer et resultat omkring nulpunktet. Hvis man læser rapporten mellem linjerne, kunne disse neuro-løsninger meget vel være til salg.
I er velkomne til at skyde det ned, men for min egen fornøjelses skyld gætter jeg på, hvad pengene for eksempel kunne bruges til.
Og alle husker, at Bittiums løsning er en vigtig del af Sinaptica-samarbejdet.